Electromedical Technologies and
Nazarbayev University
to Launch Phase
I Research
Program to
Define Potent
Electrical Frequencies Through
Animal Models
SCOTTSDALE,
AZ --
September 10, 2020 -- InvestorsHub NewsWire
-- Electromedical
Technologies, Inc. (OTC: EMED)
(the "Company"
or
"Electromedical
Technologies"),
a pioneer in the development and manufacturing of
bioelectronic
devices
designed to relieve chronic, intractable and acute pains by using
frequencies and electro-modulation, is pleased
to announce the launch of a Phase 1 research
program
in
collaboration with Nazarbayev
University
to
identify the most
effective electrical frequencies for
driving physiological responses in animal models.
Matthew
Wolfson, Founder and CEO of Electromedical Technologies,
explained,
"We
will be tapping into the revolutionary potential of
electro-modulation
with
this Phase 1 study. The core objective is deciphering
the physiological
impact
of
a wide
range of electrical
frequencies
in
animal models. Explicit
animal research will be instrumental in validating effective
electrical frequencies.
Our
unique research program will
establish a platform for enhancing
electro-modulation."
Management
notes that the Company's investment
in
this animal
research program will
advance
the
science
of
electro-modulation
and
accelerate the
development
of its applications in healthcare. Building a strong scientific
foundation today will enable
powerful advances in the technology
of electro-modulation in the
near
future.
The
Company's research
team is being
led
by Professor
Dos D. Sarbassov, a
renowned expert
in cell signaling with
intensive
postdoctoral research training at the Whitehead Institute for
Biomedical Research (MIT). Dr.
Sarbassov also worked
for many years as Faculty of the Molecular and Cellular Oncology
Department at MD Anderson Cancer Center (widely
viewed one of the foremost oncology
centers
in
the
US).
In 2019, Dr. Sarbassov joined Nazarbayev
University
to develop a
cutting-edge
biomedical research program.
"Our
studies of electro-modulation are in
a
process of transition from a simplified cell culture to
the
animal
model system,"
commented Dr.
Sarbassov.
"A
key question is to determine if
changes
in cell
signaling induced
by
specific
alternating
electrical fields will
be sufficient to lead to physiological changes in organism.
We
will study effects of electro-modulation on the
insulin-dependent
glucose uptake, pro-inflammatory
or stress-dependent
cytokine secretion,
hypertension,
tumor growth and viral infection in
mammalian
animal
models.
Regulation
of the
physiological
responses by electro-modulation will provide
a leverage for corrections of disease related physiological
defects.
The
proposed Stage
I studies in the animal models will
place a foundation for clinical applications of electro-modulation
in the Stage
II of our research and development program in collaboration with
Electromedical Technologies. Our research work by opening the door
for electro-modulation in healthcare will contribute
substantially
to
a
precision
medicine of
tomorrow."
About
Nazarbayev University:
Nazarbayev
University
(NU), established on the initiative of the first President of the
Republic of Kazakhstan in 2010, is the country's flagship academic
institution with aspirations to become a global-level research
university. This is the first university in Kazakhstan which is
guided by the principles of autonomy and academic freedom. Located
in the capital of Kazakhstan, NU is a research university with
growing international renown combining education, research and
innovation on a state of the art 21st-century campus. NU scholars
conduct research in many fields, and seek to expand human knowledge
through innovation, analysis, and collaboration. Within ten years
since its inception, NU has become a leading research university in
Kazakhstan. NU research is supported by the government of the
Republic of Kazakhstan, local and international organizations, and
is carried out in the Schools, Research Centers and Institutes.
Please visit Nazarbayev
University
website https://research.nu.edu.kz/en/ to
find comprehensive information on the NU research activities and
profiles of faculty and researchers.
About
Electromedical Technologies
Headquartered
in Scottsdale, Arizona, Electromedical Technologies, Inc. is a
commercial stage bioelectronic
medical
device manufacturing company initially focused on the treatment of
various chronic, acute, intractable and postoperative pain
conditions. Through university collaboration agreements the company
is working to develop a comprehensive research program in defining
the effects of electro-modulation on the human body by studying the
impacts of electrical fields in cell signaling and effects on virus
assembly and immune responses with the goal of improving human
well-being. The company's current cleared product indications are
for chronic acute post-traumatic and postoperative, intractable
pain relief.
Our
animal studies do not involve any human testing, and are not
related to our current products. We are conducting this research to
augment and advance the science of electro-modulation in
healthcare. The United States Food and Drug Administration
has not reviewed or approved our animal research studies
For
more information, visit www.electromedtech.com.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance or guarantee that
such expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous factors and uncertainties, including but
not limited to: adverse economic conditions, competition, adverse
federal, state and local government regulation, international
governmental regulation, inadequate capital, inability to carry out
research, development and commercialization plans, loss or
retirement of key executives and other specific risks. To the
extent that statements in this press release are not strictly
historical, including statements as to revenue projections,
business strategy, outlook, objectives, future milestones, plans,
intentions, goals, future financial conditions, events conditioned
on stockholder or other approval, or otherwise as to future events,
such statements are forward-looking, and are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The forward-looking statements contained in this
release are subject to certain risks and uncertainties that could
cause actual results to differ materially from the statements
made.
Corporate
Contact:
Electromedical Technologies,
Inc.
Matthew
Wolfson
Tel:
1.888.880.7888
email:
ceo@electromedtech.com
https://electromedtech.com
Public
Relations Contact:
Tiger Global Marketing &
Branding Agency
info@TigerGMP.com
www.TigerGMP.com